India Pharma Outlook Team | Thursday, 14 August 2025
The US market expansion through the introduction of new products in the gastrointestinal, pain management, and digestive health division’s propelled the company's reported revenue of Rs. 620 crore, up 5% year over year.Due to lower input prices and the sale of higher-cost stocks, gross profit increased 8.9% to Rs. 358.2 crore, while gross margin improved 209 basis points to 57.8%. EPS was Rs. 1.3 and EBITDA was Rs. 100.1 crore with a margin of 16.1%. The business had a healthy cash balance of Rs. 711 crore at the end of the quarter.
Mark Saldanha, Managing Director, said, “While Q1FY26 was a seasonally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in the US markets and the easing of raw material costs. While EBITDA and net profit margins were impacted by ramp-up costs, a one-time ECL provision for the emerging market division, and forex adjustments, these are transient and do not affect the fundamental momentum of our business.
Also Read: Mankind Pharma Shares Jump 32% On Their Stock Market Debut
With the Goa facility integration almost finished, we are now laser-focused on increasing capacity, improving operational efficiency, and unlocking synergies. Our execution discipline, along with a strong pipeline and growing market presence, positions us well to deliver sustainable, long-term value. We are still dedicated to driving growth, improving returns, and creating enduring value for our stakeholders in FY26 and beyond. We are already seeing encouraging early signs of demand recovery in key markets like the U.S., U.K., and Australia.
